Clinuvel Pharmaceuticals (CLVLY) News Today $7.34 +0.21 (+2.95%) As of 09/15/2025 03:58 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartDividendHeadlinesSEC FilingsShort InterestBuy This Stock CLVLY Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Health Check: At risk of third ‘strike’, Clinuvel argues its executive pay is ‘appropriate’September 14 at 11:24 PM | msn.comCLINUVEL preparing upgrade of ADR program to Level II, Nasdaq uplistAugust 22, 2025 | globenewswire.comIs Clinuvel Pharmaceuticals Limited's (ASX:CUV) Latest Stock Performance A Reflection Of Its Financial Health?May 12, 2025 | uk.finance.yahoo.comCLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105May 6, 2025 | globenewswire.comHigh Growth Tech Stocks To Watch In April 2025April 14, 2025 | finance.yahoo.comClinuvel Pharmaceuticals Ceases 19,000 Performance RightsApril 8, 2025 | tipranks.comCLINUVEL PHARMACEUTICALS Issues New Shares to Bolster Market PositionApril 6, 2025 | tipranks.comClinuvel Pharmaceuticals Expands Market Presence with New Securities QuotationApril 6, 2025 | tipranks.comClinuvel Pharmaceuticals Issues Shares Under Incentive ProgramApril 6, 2025 | tipranks.comBiocurious: While other biotechs scratch around for cash, Clinuvel is accused of having too muchApril 1, 2025 | msn.comWhy Clinuvel, Orthocell, Vulcan, and Wildcat shares are storming higherMarch 27, 2025 | msn.comClinuvel Reports Positive Results in Stroke Treatment StudyMarch 25, 2025 | tipranks.comCLINUVEL CEO Takes Temporary Leave; Operations to Continue UninterruptedMarch 17, 2025 | tipranks.comClinuvel Introduces Groundbreaking Vitiligo Program at the World's Biggest Dermatology Meeting, AAD 2025March 3, 2025 | globenewswire.comJefferies Sticks to Their Buy Rating for Clinuvel Pharmaceuticals Limited (CLVLF)March 3, 2025 | markets.businessinsider.comClinuvel Pharmaceuticals Limited (CLVLY) Q2 2025 Earnings Call TranscriptFebruary 28, 2025 | seekingalpha.comClinuvel Advances SCENESSE® Use for Adolescent EPP TreatmentFebruary 9, 2025 | tipranks.comClinuvel Pharmaceuticals Limited (CLVLF) Receives a Buy from JefferiesJanuary 19, 2025 | markets.businessinsider.comClinuvel Advances in Vitiligo Treatment with SCENESSE®January 19, 2025 | tipranks.comCLINUVEL Expands SCENESSE® Distribution to ArgentinaJanuary 16, 2025 | tipranks.comClinuvel’s SCENESSE® Drug Application Validated by Health CanadaDecember 22, 2024 | tipranks.comClinuvel Pharmaceuticals Focuses on Long-Term Growth Amid Market ChallengesDecember 22, 2024 | tipranks.comClinuvel Pharmaceuticals Updates Trading Policy Amid Growth FocusDecember 18, 2024 | tipranks.comExploring High Growth Tech Stocks in Australia December 2024December 5, 2024 | finance.yahoo.comClinuvel Navigates Market Challenges with Strategic FocusDecember 4, 2024 | tipranks.comClinuvel Pharmaceuticals Adjusts Securities PortfolioDecember 3, 2024 | tipranks.comCLINUVEL files Canadian New Drug Submission for SCENESSE® in EPPSeptember 30, 2024 | globenewswire.comClinuvel Pharmaceuticals goes ex dividend MondaySeptember 6, 2024 | msn.comClinuvel Pharmaceuticals Limited (CLVLF) Gets a Buy from MorgansAugust 30, 2024 | markets.businessinsider.comASX Health Stocks: Clinuvel, MedAdvisor rally after hitting high notes on profitsAugust 29, 2024 | msn.comAfamelanotide in fair-skinned Parkinson's patientsJune 17, 2024 | globenewswire.comPhotomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German InvestorsMarch 28, 2024 | globenewswire.comClinuvel Pharmaceuticals (ASX:CUV) shareholders have endured a 50% loss from investing in the stock three years agoMarch 21, 2024 | finance.yahoo.comClinuvel Pharmaceuticals Ltd ADR (CLVLY)March 20, 2024 | investing.comThe Clinuvel Pharmaceuticals share price is up 236% in 12 monthsMarch 9, 2024 | fool.com.auMalibu shines a light on CLINUVEL's pioneering work in photomedicineMarch 4, 2024 | globenewswire.comClinuvel Pharmaceuticals Ltd. ADRMarch 2, 2024 | wsj.comClinuvel Pharmaceuticals (CLVLF) Price Target Increased by 5.58% to 19.75February 25, 2024 | msn.comClinuvel Pharmaceuticals GAAP EPS of A$0.22, revenue of A$32.25BFebruary 23, 2024 | msn.comClinuvel Pharmaceuticals Ltd.January 30, 2024 | wsj.comClinuvel Pharmaceuticals Ltd ADRDecember 9, 2023 | morningstar.comMClinuvel Pharmaceuticals Ltd ADR CLVLYDecember 2, 2023 | morningstar.comMClinuvel Pharmaceuticals Ltd - ADR (CLVLY) Price Target Increased by 18.27% to 21.08October 31, 2023 | nasdaq.comClinuvel Pharmaceuticals (ASX:CUV) shareholders have endured a 38% loss from investing in the stock three years agoOctober 5, 2023 | finance.yahoo.comClinuvel Pharmaceuticals (CLVLF) Price Target Increased by 12.19% to 18.70September 1, 2023 | msn.comCould The Market Be Wrong About Clinuvel Pharmaceuticals Limited (ASX:CUV) Given Its Attractive Financial Prospects?May 3, 2023 | finance.yahoo.comSome Patients With a Rare Disease Face Hurdles Getting the Only TreatmentMay 1, 2023 | msn.comClinuvel Pharmaceuticals (ASX:CUV) shareholders have earned a 14% CAGR over the last five yearsMarch 30, 2023 | finance.yahoo.comAnalysts Just Slashed Their Clinuvel Pharmaceuticals Limited (ASX:CUV) EPS NumbersMarch 1, 2023 | finance.yahoo.comCLINUVEL Launches CYACÊLLE, Next Generation Solar CareMarch 1, 2023 | finance.yahoo.com Get Clinuvel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CLVLY and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CLVLY Media Mentions By Week CLVLY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLVLY News Sentiment▼-1.250.92▲Average Medical News Sentiment CLVLY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLVLY Articles This Week▼10▲CLVLY Articles Average Week Get the Latest News and Ratings for CLVLY and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Clinuvel Pharmaceuticals and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies AALBF News AGRPY News AICAF News EADSF News AIPUY News AKBTY News AABB News AUTLF News DFRYF News BMDPF News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:CLVLY) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredDalio’s $319 Million Gold BetA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredIf you own dollars, read this...Former Goldman Exec: "A Strange Day Is Coming to America" Dr. David Eifrig, who warned of inflation months ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clinuvel Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Clinuvel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
